Pharmacokinetics and dosimetry studies for optimization of pretargeted radioimmunotherapy in CEA-expressing advanced lung cancer patients

Frontiers in Medicine

Volumn 2, Issue NOV, 2015, Pages

  Bodet Milin, Caroline ^a,b   Ferrer, Ludovic ^b,c   Rauscher, Aurore ^b,c   Masson, Damien ^a   Rbah Vidal, Latifa ^b   Faivre Chauvet, Alain ^a,b   Cerato, Evelyne ^a   Rousseau, Caroline ^b,c   Hureaux, José ^d   Couturier, Olivier ^d   Salaün, Pierre Yves ^e   Goldenberg, David M ^f,g   Sharkey, Robert M ^g   Kraeber Bodéré, Françoise ^a,b,c   Barbet, Jacques ^b,h  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Team 12   (France)

^c UMR INSERM U892 CNRS 6299   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e BREST UNIVERSITY HOSPITAL   (France)

^f IBC Pharmaceuticals Inc   (United States)

^g IMMUNOMEDICS INC   (United States)

^h GIP ARRONAX   (France)

Author keywords

Dosimetry; Lung cancer; Pharmacokinetics; Pretargeting; Radioimmunotherapy; Scintigraphy; SPECT; SPECT CT

Indexed keywords

EID: 84997401720     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2015.00084     Document Type: Article

References (28)

1. Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer (2015) 15(6):347-60. doi: 10.1038/nrc3925
2. Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Eugène T, Pallardy A, Frampas E, et al. Radioimmunoconjugates for the treatment of cancer. Semin Oncol (2014) 41(5):613-22. doi:10.1053/j.seminoncol.2014.07.004
3. Barbet J, Kraeber-Bodéré F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm (1999) 14(3):153-66. doi:10.1089/cbr.1999.14.153
4. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol (2006) 24(5):823-34. doi:10.1200/JCO.2005.03.8471
5. Juweid M, Sharkey RM, Behr T, Swayne LC, Herskovic T, Pereira M, et al. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med (1996) 37(6):905-11
6. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol (2005) 23(27):6763-70. doi:10.1200/JCO.2005.18.622
7. Kraeber-Bodéré F, Faivre-Chauvet A, Saï-Maurel C, Gautherot E, Fiche M, Campion L, et al. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. J Nucl Med (1999) 40(1):198-204
8. Gautherot E, Rouvier E, Daniel L, Loucif E, Bouhou J, Manetti C, et al. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. J Nucl Med (2000) 41(3):480-7
9. Kraeber-Bodéré F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez JP, Murat A, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res (1999) 5(10 Suppl):3190s-8s
10. Vuillez JP, Kraeber-Bodéré F, Moro D, Bardiès M, Douillard JY, Gautherot E, et al. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial. Clin Cancer Res (1999) 5(10 Suppl):3259s-67s
11. Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French endocrine tumor group. J Clin Oncol (2006) 24(11):1705-11. doi:10.1200/JCO.2005.04.4917
12. Salaün PY, Campion L, Bournaud C, Faivre-Chauvet A, Vuillez JP, Taieb D, et al. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J Nucl Med (2012) 53(8):1185-92. doi:10.2967/jnumed.111.101865
13. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A (2006) 103(18):6841-6. doi:10.1073/pnas.0600982103
14. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med (2008) 49(1):158-63. doi:10.2967/jnumed.107.046185
15. Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med (2010) 40(3):190-203. doi:10.1053/j.semnuclmed.2009.12.002
16. Schoffelen R, Woliner-van der Weg W, Visser EP, Goldenberg DM, Sharkey RM, McBride WJ, et al. Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. Eur J Nucl Med Mol Imaging (2014) 41(8):1593-602. doi:10.1007/s00259-014-2742-6
17. Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, et al. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res (2003) 9(10 Pt 2):3973S-81S
18. McBride WJ, Zanzonico P, Sharkey RM, Norén C, Karacay H, Rossi EA, et al. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med (2006) 47(10):1678-88
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 45(2):228-47. doi:10.1016/j.ejca.2008.10.026
20. Lavielle M, Mentré F. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn (2007) 34(2):229-49. doi:10.1007/s10928-006-9043-z
21. Ogawa K, Harata Y, Ichihara T, Kubo A, Hashimoto SA. Practical method for position-dependent Compton-scatter correction in single photon emission CT. IEEE Trans Med Imaging (1991) 10:408-12. doi:10.1109/42.97591
22. Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, et al. MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med (2012) 53(8):1310-25. doi:10.2967/jnumed.111.100123
23. Kikinis R, Pieper S. 3D Slicer as a tool for interactive brain tumor segmentation. Conf Proc IEEE Eng Med Biol Soc (2011) 2011:6982-4. doi:10.1109/IEMBS.2011.6091765
24. Ferrer L, Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener WA, et al. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer (2010) 116(4 Suppl):1093-100. doi:10.1002/cncr.24797
25. Toussaint N, Souplet J-C, Fillard P. MedINRIA: medical image navigation and research tool by INRIA. Proc. of MICCAI '07 Workshop on Interaction in Medical Image Analysis and Visualization. Brisbane, QLD (2007)
26. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna. Available from: http://www.R-project.org/
27. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab (1996) 16(1):42-52. doi:10.1097/00004647-199601000-00005
28. Frampas E, Maurel C, Remaud-Le Saëc P, Mauxion T, Faivre-Chauvet A, Davodeau F, et al. Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. Eur J Nucl Med Mol Imaging (2011) 38(12):2153-64. doi:10.1007/s00259-011-1903-0